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Lymphocyte proliferation assay 163
Blood samples were taken (at days 0, 14, 28, 42 and 56) in heparinized tubes 164 (Monoject, Mansfield, MA, USA). The peripheral blood mononuclear cells (PBMC) were 165 purified by density gradient centrifugation using Ficoll-Hypaque-1077 (Sigma-Aldrich, 166 Oakville, ON, Canada) according to the manufacturer's instructions. The purified PBMC 167
were resuspended at a concentration of 2 x 10 6 cells/mL in RPMI 1640 culture medium 168 supplemented with 10% of fetal bovine serum (FBS), 2 mM glutamine, 50 µM ß-169 mercaptoethanol, and 100 U/mL penicillin/streptomycin. A 100 µl aliquot was dispatched 170
into each well of a 96-well plate. One hundred µl of rP97c or total M. hyopneumoniae 171 proteins (which both contain a total of 10 µg of protein/mL) were added to each well in 172 triplicate. As a positive control, cells were also stimulated with Concanavalin (ConA) at a 173 final concentration of 10 µg/mL. After 48 hrs incubation at 37°C with 5% CO 2 , cells were 174 treated with 10 µM BrdU (Exalpha Biologicals Inc, MA. USA) and incubated for an 175 additional period of 16 hrs. The cell incorporation of BrdU was measured using the BrdU 176
Cell Proliferation Assay Kit (Exalpha Biologicals) according to the manufacturer's 177 instructions. The stimulation index (SI) was calculated by dividing the 450 nm absorbance 178 results of the stimulated cells by the 450 nm absorbance results of the non-stimulated cells. 179 180 2.6. Cytological and cytokine analysis in the BALF 181 Bronchoalveolar lavage fluids (BALF) were collected at necropsy (day 56 after the 182 first vaccination) as previously described [6] . Briefly, a volume of 30 mL of sterile PBS was 183 infused into the lung using an 18-gauge catheter attached to a syringe. The BALF were 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 aspired back and passed through a single layer of gauze to remove gross mucus. 185
Approximately 20 mL of the BALF was retrieved and immediately kept on ice. 186
The number of total leukocytes was determined manually using a hemacytometer. 187
The differential cell counts of leukocytes were made using the Shandon cytospin 4 machine 188 (Shandon Inc., Pittsburgh, Pa, USA). The cells were stained by cytocentrifugation using the 189 Diff-Quick staining method. 4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11
In vitro M. hyopneumoniae growth inhibition assay 208
The M. hyopneumoniae growth inhibition assay was performed as described 209 previously with slight modifications [29] . Briefly, 100 µl aliquots containing 10 5 CCU of the 210 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14
M. hyopneumoniae growth inhibition in vitro 275
As shown in Fig. 4 , sera from rAdP97c vaccinated pigs inhibited the growth of 276 mycoplasma cells in a dose dependent manner. A significant mycoplasma growth inhibitory 277 effect could also be observed within sera from animals vaccinated with Suvaxyn® MH-one 278 and was higher compared to rAdP97c vaccinated animals. As expected, no mycoplasma 279 growth inhibitory activity was observed within sera of non-vaccinated animals. 280 281
Bacteriological and pneumonic findings 282
One week after the challenge, a non-productive coughing was observed in all 283 challenged groups with a lesser extend in Suvaxyn® MH-one vaccinated animals (data not 284 shown). No macroscopic lung lesions were observed in the control animals group. In 285 contrast, the pneumonic lesions characteristics of PEP were present in all infected animals 286 (Fig. 5) . The unvaccinated and infected pigs had the higher percentage of pneumonic lesions 287 (45.8% ± 11.5). In comparison to this group, the pigs vaccinated with rAdP97c and 288 Suvaxyn® MH-one had significantly lower percentage of pneumonic lesions with means of 289 18.5% ± 9.6 and 1.3% ± 1.7, respectively. No statistical difference was found between the 290 uninfected animals and Suvaxyn® MH-one vaccinated and challenged animals. Noteworthy, 291 a significant difference was observed between the infected and rAdP97c vaccinated animals 292 compared to uninfected animals. After examining the microscopic lung lesions by 293 hematoxylin-oesine staining, the presence of nodular lymphoid hyperplasia was observed 294 around the bronchioles in the lung tissues from all challenged groups (data not shown). As 295 expected no M. hyopneumoniae was recovered in the samples from the control group. In 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15 lower amount in rAdP97c and Suvaxyn® MH-one vaccinated animals compared to 298 unvaccinated animals (P < 0.05 and P < 0.001, respectively) (Fig. 5) . The amount of M. 299 hyopneumoniae retrieved in BALF and lungs from Suvaxyn® MH-one vaccinated animals 300 was significantly lower than in rAdP97c vaccinated animals (P < 0.001 and P < 0.01, 301 respectively). Overall, the amount of M. hyopneumoniae retrieved from lungs of infected 302 animals was higher compared to BALF (P < 0.001). 303 ADG values between the unvaccinated and rAdP97c vaccinated challenge animals during the 316 course of the experiment but there were significant differences when they were compared to 317 control animals at days 42 and 56 post-vaccination. Nonetheless, the mean ADG value of 318 rAdP97c vaccinated animals was slightly higher compared to unvaccinated animals with the 319 consequence that Suvaxyn® MH-one vaccinated animals ADG value was statistically 11  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49 Table 1 . HerdChek M. hyopneumoniae Antibody ELISA assay antibodies detection results.
Experimental groups
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Fig.2. P97c specific IgG1 and IgG2a antibodies production in vaccinated pigs.
ELISA assays were performed using rP97c as an antigen and with sera and saliva.
Experimental groups: unvaccinated and uninfected control animals (Ctl); unvaccinated and infected animals (Unvac); Suvaxyn® MH-one vaccinated and infected animals (MHone); rAdP97c vaccinated and infected animals (rAdP97c). *P < 0.05; **P < 0.01; *** P < 0.001 (significant difference between IgG1 and IgG2a). 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 30 sets of data are labeled with superscripts of different letters or when only one set is labeled with a superscript, it indicates that these 2 sets of data are statistically different (P < 0.05). unvaccinated and uninfected control animals (Ctl); unvaccinated and infected animals (Unvac); Suvaxyn® MH-one vaccinated and infected animals (MH-one); rAdP97c vaccinated and infected animals (rAdP97c). BALF: bronchoalveolar lavage fluid; CCU:
color changing unit; ADG: average daily weight gain. When 2 sets of data are labeled with superscripts of different letters or when only one set is labeled with a superscript, it indicates that these 2 sets of data are statistically different (P < 0.05). were collected at necropsy as described in the materials and methods section.
Macrophages (Mac); neutrophils (Neu); lymphocytes (Lym). When 2 sets of data are labeled with superscripts of different letters or when only one set is labeled with a superscript, it indicates that these 2 sets of data are statistically different (P < 0.05).
